Document Type : Original Communication
Keywords
Subjects
Introduction
Huntington's Disease (HD) is an autosomal dominant inherited progressive neurodegenerative disease caused by an expansion in CAG trinucleotide repetition encoding polyglutamine in the structure of Huntingtin IT15 (HTT) protein located on the short arm of chromosome 4 (1). The basic radio-pathological process is characterized by prominent cell loss and atrophy in the striatum (2). Neuropsychiatric disorders may present with symptoms such as apathy, irritability, impulsivity, and obsessiveness, which can be described as hypo-frontal or executive dysfunction syndrome long before the manifest stage, many of which are undiagnosed at this stage (3). In this case series, psycho-functional decline along with functional and cognitive impairment in specific domains that should be recognized beyond the motor findings of HD in clinical practice was investigated, and these findings were correlated with morphometric descriptions on a radiological basis.
Ten preliminary clinically and genetically diagnosed advanced-stage Huntington's disease patients were evaluated with UHDRS' four main domains (4) and psychofunctional scales. Each of the motor, functional, cognitive, behavioral, and neuropsychiatric scales was evaluated in each patient at the first and second visits (3 months after the first visit) by the corresponding author (E.D.U) and two other clinical neuroradiologists blinded to the patient's information. The neuroradiological correlations of each scale with the morphometric measurement analysis results were evaluated. The case series study was conducted in accordance with the Helsinki Declaration. Written consent was obtained from each participant.
The study was conducted in accordance with the Helsinki Declaration. The study was planned as a 'Case Series.' Approval was granted by a written consent (Informed Volunteer Consent Form) form obtained from each participant by the corresponding author and declared to the center (Nevşehir State Hospital Administrative Unit). The consent form, patient demographic, and clinical and imaging information of each patient included in the study were recorded and stored in the patient forms by the corresponding author.
2.1. Rating Scales
2.1.1. Analysis of UHDR Domains
Motor and behavioral domains in HD were assessed by the UHDRS in order to see to what extent daily life activities are restricted and in which areas (4). Motor disability was evaluated in 5 main domains: Oculomotor (ocular pursuit, saccade initiation, saccade velocity), bradykinesia, rigidity (arms), dystonia (trunk, right upper extremity, left upper extremity, right lower extremity, left lower extremity), chorea (face, body, trunk, right upper extremity, left upper extremity, right lower extremity, left lower extremity). The behavioral section of the UHDRS consists of 11 items assessing the frequency and severity of complaints about mood/sadness, low self-esteem or guilt, anxiety, suicidal thoughts, disruptive or aggressive behavior, irritable behavior, obsessions, compulsions, delusions, and hallucinations. The functional capacity evaluation was assessed using the UHDRS scale with total functional capacity (TFC) and functional assessment scale (FAS). TFC is a sum of detailed measurements of functional capacity that consists of five global items that evaluate occupation, finances, domestic chores, activities of daily living, and care level, with scores on each item ranging from 0 to either 2 or 3 (e.g., "occupation — 0= unable, 1=marginal work only, 2= reduced capacity for the usual job, 3=normal") (5). The FAS is a more comprehensive measurement that evaluates tasks related to the occupation (e.g., accustomed/volunteer work), finances (financial management), activities of daily living (e.g., social engagement, self-care), domestic chores (e.g., home maintenance, laundry), level of care (e.g., home or supervised), and physical abilities (e.g., walking, getting out of bed, falls). The UHDRS (4) cognitive component consists of 3 tests that measure cognitive executive functions: The Stroop Color and Word Test (SCWT) (6), a verbal fluency test (VFT) (7), and the Symbol Digit Modalities Test (SDT) (8). The SCWT (6) is a neuropsychological test that assesses the ability to inhibit cognitive interference, which occurs when the processing of a stimulus feature affects the simultaneous processing of another attribute of the same stimulus. The VFT is a commonly used neuropsychological test and mainly examines the ability to spontaneously produce words orally within a fixed period. 2 types of verbal fluency ability, i.e., letter fluency and category fluency, are evaluated. The SDT is a matching test in which the participants are asked to match 9 abstract symbols with numerical digits using code. Only the written response format of the SDMT was administered.
2.1.2. Psychofunctional Evaluation
In the psychofunctional evaluation, the background information of each patient and the first neuropsychiatric finding before HD diagnosis, the date of the first application to the physician for this purpose, the time elapsed until the diagnosis of HD, the psychiatric diagnoses taken so far, and the neuropsychiatric drugs were evaluated. In the psychofunctional evaluation, Parkinson's Sleep Scale (PDSS) (sleep) (9), Questionnaire for Impulsive-Compulsive Disorders in Parkinson's Disease - Rating Scale (QUIP-RS) (impulsiveness) (10), Starkstein's Apathy Scale (SAS) (apathy) (11), Hamilton Depression Rating Scale (HDRS) (depression) (12), and Hamilton Anxiety Rating Scale (HAM-A) (anxiety) (13) were evaluated.
2.2. Morphometric Evaluation
Cranial images of the participants were obtained on the AW Volume Share 7 workstation using a 3-T Signa MR scanner (General Electric, Milwaukee, WI), and a T2 sequence of MRI was used. In morphometric assessment, bicaudate ratio (BCR), bifrontal ratio (BFR), frontal horn area (FHA), frontal
|
Table 1. UDRS motor, cognition, behavior domains and TFC domains were compared with MRI morphometric measurements. |
||||||||||||
|
|
UHDRS motor score |
UHDRS cognition score |
Functional Assessment Scale |
Total Functional Capacity |
||||||||
|
Ocular Pursuit |
Bradykinesia |
Rigidity |
Dystonia |
Chorea |
SDMT |
SIT |
VFT |
|
||||
|
Intercaudate Distance (mm) |
rho=0,583 p=0,077 |
rho=-0,505 p=0,137 |
rho=0,415 p=0,233 |
rho=0,284 p=0,426 |
rho=0,284 p=0,426 |
rho=-0,226 p=0,531 |
rho=-0,537 p=0,110 |
rho=-0,775 p=0,008 |
rho=-0,505 p=0,137 |
rho=-0,836 p=0,003 |
|
|
|
|
||||||||||||
|
|
||||||||||||
|
|
||||||||||||
|
|
||||||||||||
|
|
||||||||||||
|
Bicaudate |
rho=0,311 p=0,381 |
rho=-0,686 p=0,028 |
rho=0,681 p=0,030 |
rho=0,251 p=0,484 |
rho=0,251 p=0,484 |
rho=-0,511 p=0,131 |
rho=-0,775 p=0,008 |
rho=-0,497 p=0,144 |
rho=-0,686 p=0,028 |
rho=-0,671 p=0,034 |
|
|
|
Ratio |
|
|||||||||||
|
Frontal Horn Distance (mm) |
rho=0,291 p=0,414 |
rho=-0,634 p=0,049 |
rho=0,791 p=0,006 |
rho=0,426 p=0,219 |
rho=0,426 p=0,219 |
rho=-0,598 p=0,068 |
rho=-0,354 p=0,316 |
rho=0,043 p=0,906 |
rho=-0,634 p=0,049 |
rho=-0,308 p=0,386 |
|
|
|
Bifrontal |
rho=0,206 p=0,567 |
rho=-0,606 p=0,034 |
rho=0,714 p=0,020 |
rho=0,394 p=0,259 |
rho=0,394 p=0,259 |
rho=-0,560 p=0,092 |
rho=-0,237 p=0,510 |
rho=0,161 p=0,656 |
rho=-0,606 p=0,034 |
rho=-0,280 p=0,433 |
|
|
|
Ratio |
|
|||||||||||
|
Bifrontal Distance/ Caudate Dsitance |
rho=-0,361 p=0,306 |
rho=0,394 p=0,260 |
rho=-0,221 p=0,540 |
rho=-0,071 p=0,845 |
rho=-0,071 p=0,845 |
rho=0,091 p=0,802 |
rho=0,512 p=0,130 |
rho=0,763 p=0,010 |
rho=0,394 p=0,260 |
rho=0,631 p=0,039 |
|
|
|
Frontal Horn Area (Right, mm) |
rho=0,208 p=0,564 |
rho=-0,695 p=0,026 |
rho=0,778 |
rho=0,355 p=0,314 |
rho=0,355 p=0,314 |
rho=-0,573 p=0,083 |
rho=-0,598 p=0,068 |
rho=-0,148 p=0,684 |
rho=-0,695 p=0,026 |
rho=-0,459 p=0,182 |
|
|
|
p=0,008 |
|
|||||||||||
|
Frontal Horn Area Left, mm) |
rho=0,208 p=0,564 |
rho=-0,548 p=0,101 |
rho=0,675 p=0,032 |
rho=0,213 p=0,554 |
rho=0,213 p=0,554 |
rho=-0,689 p=0,028 |
rho=-0,677 p=0,032 |
rho=-0,240 p=0,504 |
rho=-0,548 p=0,101 |
rho=-0,555 p=0,046 |
|
|
|
Caudate Area (Superior, mm) |
rho=-0,160 p=0,659 |
rho=0,679 p=0,031 |
rho=-0,729 p=0,017 |
rho=-0,321 p=0,366 |
rho=-0,321 p=0,366 |
rho=0,489 p=0,151 |
rho=0,697 p=0,025 |
rho=0,253 p=0,480 |
rho=0,679 |
rho=0,440 p=0,203 |
|
|
|
p=0,031 |
|
|||||||||||
|
Magnetic Resonance Imaging Morphometric Evalution |
Caudate Area (Middle, mm) |
rho=-0,097 p=0,790 |
rho=0,554 p=0,047 |
rho=-0,558 p=0,044 |
rho=-0,569 |
rho=-0,569 p=0,036 |
rho=0,299 p=0,402 |
rho=0,317 p=0,372 |
rho=-0,043 p=0,906 |
rho=0,554 p=0,047 |
rho=0,370 p=0,292 |
|
|
p=0,036 |
|
|||||||||||
|
Caudate Area (İnferior, mm) |
rho=-0,472 p=0,169 |
rho=0,382 p=0,277 |
rho=-0,311 p=0,381 |
rho=-0,355 p=0,314 |
rho=-0,355 p=0,314 |
rho=0,250 p=0,486 |
rho=0,177 p=0,625 |
rho=0,382 p=0,277 |
rho=0,382 p=0,277 |
rho=0,665 p=0,036 |
|
|
|
Caudate Volume (Right) |
rho=-0,243 p=0,498 |
rho=0,525 p=0,119 |
rho=-0,436 p=0,208 |
rho=-0,392 p=0,262 |
rho=-0,392 p=0,262 |
rho=0,232 p=0,518 |
rho=0,321 p=0,366 |
rho=0,222 p=0,537 |
rho=0,525 p=0,119 |
rho=0,605 p=0,044 |
|
|
|
Caudate Volume (Left) |
rho=-0,299 p=0,401 |
rho=0,562 p=0,041 |
rho=-0,482 p=0,159 |
rho=-0,499 p=0,142 |
rho=-0,499 p=0,142 |
rho=0,223 p=0,535 |
rho=0,388 p=0,267 |
rho=0,324 p=0,361 |
rho=0,562 |
rho=0,633 p=0,049 |
|
|
|
p=0,041 |
|
|||||||||||
|
Caudate Volume Ratio (Right) |
rho=-0,354 p=0,350 |
rho=0,672 p=0,047 |
rho=-0,454 p=0,219 |
rho=-0,365 p=0,334 |
rho=-0,365 p=0,334 |
rho=0,276 p=0,472 |
rho=0,403 p=0,282 |
rho=0,395 p=0,293 |
rho=0,672 p=0,047 |
rho=0,670 p=0,048 |
|
|
|
Unified Huntington's Disease Rating Scale (UHDRS), Symbol Digit Modalities Test (SDMT), Stroop Interference Test (SIT), Verbal Fluency Test (VFT) |
||||||||||||
horn ratio to intercaudate distance (FH/CC), and caudate volume and caudate volume ratio (CVR) were analyzed and
correlated with relevant parameters. BCR was calculated by dividing the frontal horns' caudate indentations by the brain's width on the same line (14). Bifrontal Ratio (BFR) measurements were obtained by dividing the distance between the most lateral ends of the frontal horns by the width of the brain on the same line using the same section (15). The caudate volume ratio (CVR) was calculated via the perimeters of the caudate, beginning at the level immediately superior to that in which the anterior commissure was observed. The borders of the caudate nucleus were determined laterally by the anterior limb of the internal capsule and medially by the frontal horn or lateral ventricle body. Three different sections were used for caudate volume measurements; the first section is the most superior slice, measured just inferior to the slice in which the caudate body was observed; the second was located superiorly through the level just below that in which the body of the caudate was observed; the third most inferior section was superior to the slice containing anterior commissure. Caudate volumes were calculated separately by summing the areas from all slices and multiplying this sum by slice thickness (7 mm). The caudate volume ratio was calculated by dividing the volume by the brain area in the section where BCR and BFR measurements were made and multiplying by 100. Frontal horn areas (FHA) were measured where BCR and BFR measurements were made. The frontal horn ratio was obtained by dividing the total area of the frontal horns by the brain area and multiplying by 100. The frontal horn area/inter caudate distance (FH/CC) ratio was obtained by dividing the frontal horn distance and the caudate distance (16).
2.3. Results
The average age of the patients included in the study was 52.3±2, and the most common neurologic/psychiatric comorbidities were neuropathic pain (40%) and psychosis (60%). Years since the psychiatric diagnosis was 8.5±2, the year was longer than the clinical diagnosis in all patients (±2 y). UHDRS TFC score average was 5.60±2.27 (ranges between 1-9), and the most frequent functional decline was observed in occupational and financial ability. The FAS score average was 11.10±3.48 (range between 8-18), and impairments in social/financial engagement and self-care were the most common findings. Cognitive decline was present in each domain, and dominant disturbance was observed in quick thinking, adequate and timely response to reactions (VFT was 17.7±2, SDMT 23.4±2, and SIT 34.4±2 for color, 24.7±2 for word and 20.2±2 for color-word, respectively).
The PDSS score was low in correlation with a disease duration of 39.40±16.33 (22-71). The mean ICD-related behavior score was lower than the average population (8.9±2), and the most common deficit was performing tasks or hobbies (8.90±3.73). A relatively high frequency was observed in apathy (24.50±4.03), and it showed augmentation in proportion to the duration of the disease. HDRS and HAM-A mean scores were 31.00±7.53 and 30.00±6.48, ranging from 18 to 39 and 18-37, respectively.
In a morphometric evaluation in line with the duration of the disease, an increase in frontal horn distance (29.99±4.00 (mean±SD)), bifrontal ratio (0.25±0.04 (mean±SD)), and a frontal horn area (88.30±14.70 for right and 85.68±15.93 for left) were determined. The increase in the right frontal area was relatively higher than the left side. There was a decrease in caudate volume in all measured sections, and a significant volume loss was observed, especially in the inferior section (73.94±7.75 (superior), 88.67±12.45 (middle), and 21.65±7.30 (inferior), respectively). Caudate volume loss was more severe on the right (6.50±1.18 (right) and 6.65±1.05 (left). Similarly, the caudate volume ratio was found to be lower on the right (5.53±1.09 (right) and 5.66±0.79 (left). The inter caudate distance (20.98±3.69 (mean±SD)) and bifrontal distance/ caudate distance (1.40±0.21 (mean±SD)) increase were determined.
2.3.1. Correlation Analyses
A Spearman correlation coefficient for the relationships between MRI morphometric measurements and UHDRS domains is demonstrated in Table 1. UHDRS motor domains showed a positive correlation between bradykinesia and BCR (rho=0.782), FHD (rho=0.617), FHAs (rho=0.775 for right and rho=0.884 for left, respectively). The caudate area (superior) (rho=-0.763) was found to be negatively correlated with it. Similar to bradykinesia, a positive correlation was found between rigidity and BCR (rho=0.681), FHD (rho=0.791), and FHA (rho=0.778 for the right and rho=0.675 for left). A negative correlation was found between the caudate area (superior and middle) (rho=-0.729 for superior and rho=-0.558 for middle) and rigidity. A negative statistically significant relationship was found between dystonia, chorea, and the caudate area (middle) (rho=-0.569 for dystonia and rho=-0.569 for chorea, respectively). In the UHDRS cognitive domains, a negative correlation was found between SDMT and FHA (left) (rho=-0.689) and between SIT and BCR (rho=-0.775), FHA (left) (rho=-0.677). A statistically significant positive correlation was found between FHA (left) and caudate area (superior) (rho=0.697). Also, a significant negative correlation was found between VFT and intercaudate distance, bifrontal distance/ caudate distance (rho=-0.775 and rho=0.763). In UHDRS functional domains, a positive correlation was found between TFC and caudate volume (right and left) (rho=0.665 and rho=0.633), CVR (rho=0.670), and BFD (rho=0.631), while there was a negative correlation between BCR (rho=-0.671) and TFC.
There was a negative correlation between PDSS and inter caudate distance (rho=-0.559) and a positive correlation between bifrontal distance/ caudate distance (rho=0.559). A negative correlation was found between QUIP-RS and FHD (rho=-0.671) and FHA (right) (rho=-0.56). A positive relationship was found between HDRS, HAM-A, and FHD (rho=0.61 and rho=0.571, respectively) (Table 2).
Our study evaluated the functional, cognitive, behavioral, and motor domains of UHDRS and brain morphometric measurements and determined correlation analyses. In correlation analyses, a striking decline in almost all domains was observed, which is in correlation with other current studies (17). Current data emphasize that the decrease in
|
Table 2. MRI morphometric measurement values and neuropsychiatric scales were compared. |
||||||
|
|
Neuropsychiatric Scales |
|||||
|
PDSS |
QUIP-RS |
SAS |
HDRS |
HAM-A |
||
|
Intercaudate Distance (mm) |
rho=-0,559 |
rho=-0,345 p=0,329 |
rho=0,477 p=0,164 |
rho=0,274 p=0,443 |
rho=0,286 p=0,424 |
|
|
p=0,043 |
||||||
|
Frontal Horn Distance (mm) |
rho=-0,073 p=0,841 |
rho=-0,671 p=0,034 |
rho=0,483 p=0,157 |
rho=0,610 |
rho=0,571 p=0,034 |
|
|
Magnetic Resonance Imaging Morphometric Evalution |
rho=0,571 |
|||||
|
p=0,021 |
||||||
|
Bifrontal Distance/ Caudate Dsitance |
rho=0,559 p=0,043 |
rho=0,098 p=0,787 |
rho=-0,194 p=0,590 |
rho=-0,256 p=0,475 |
rho=-0,255 p=0,476 |
|
|
Frontal Horn Area (Right, mm) |
rho=-0,152 p=0,675 |
rho=-0,56 |
rho=0,401 p=0,250 |
rho=0,482 p=0,159 |
rho=0,486 p=0,154 |
|
|
rho=-0,622 |
||||||
|
p=0,042 |
||||||
|
Frontal Horn Area Left , mm) |
rho=-0,152 p=0,675 |
rho=-0,622 p=0,035 |
rho=0,552 p=0,048 |
rho=0,268 p=0,454 |
rho=0,316 p=0,374 |
|
|
Parkinson’s Sleep Scale (PDSS), Questionnaire for Impulsive-Compulsive Disorders in Parkinson's Disease – Rating Scale (QUIP-RS), Starkstein‘s Apathy Scale (SAS), Hamilton Depression Rating Scale (HDRS), Hamilton Anxiety Rating Scale (HAM-A) |
||||||
intercaudate distance, which is an essential indicator of caudate atrophy, and the decrease in the bifrontal distance, which is an indicator of widespread cortical atrophy, are important indicators of the progression of neurodegenerative disorders (18). Additionally, in a study conducted with premorbid HD patients, the SCL-90 Global Severity Index and Frontal Systems Behavior Scale (FrSBe) were compared with control individuals, and a statistically significant difference was found between the two groups (19). Similarly, in multiple sclerosis, one of the neurodegenerative diseases, Batista et al. reported that neocortex and basal ganglia volumes can be used to evaluate executive functions and that they decrease in correlation with the decline of these functions, especially in the advanced neurodegeneration process (20). Studies have shown that individuals with frontotemporal lobar degeneration (FTLD) initially present as a non-amnestic degenerative syndrome and tend to present primarily with behavioral and language-predominant symptoms, in which behavioral disinhibition is observed primarily with deficits in executive functions (21). As the degree of cerebral degeneration increases, deterioration is observed in both neurocognitive and functional domains and psychofunctional domains that the existing studies point to caudate volume reduction, ventricular enlargement, and widespread cortical atrophy in HD (22). In light of the current findings in this case series, it was found that there was a strong association between bradykinesia and rigidity and caudate atrophy and its indicators, and frontal lobe atrophy and its indicators were primarily associated with cognitive domains that a severe decline was observed mainly in episodic memory, processing speed, executive functioning, and visuospatial perception based on current data in similar studies. Functional disability is closely related to caudate and frontal lobe atrophy and its indicators. Although there are no objective, comprehensive studies to compare our current correlation data in HD, our case study has shown that frontal lobe atrophy and its indicators may be important indicators of personality/behavioral deterioration in HD.
In this case series study, HD was evaluated multifacetedly from neurocognitive and psychofunctional perspectives. The most frequent and severe decline in the relevant domains was determined, and its relationship with cerebral neurodegenerative processes was examined by morphometric evaluation of the relevant domains. Defining the neurocognitive and psychofunctional reflections of cerebral neurodegenerative effects, which begin long before clinical findings in HD, with cranial images and making a morphometric naming are essential for pre-mortal stage diagnosis and prognosis. This pioneering study is a guide for management, especially for making a correlation in advanced-stage HD in neurocognitive, psychofunctional, and neuroradiological axes. Further studies with more comprehensive scales are needed.
Acknowledgments
This study was performed in line with the principles of the Declaration of Helsinki. Informed consent was obtained from all individual participants included in the study. The study was planned as a 'Case Series' and approval was granted by written consent (Informed Volunteer Consent Form) form that was obtained from each participant by the corresponding author, and has been declarated to the center (Nevşehir State Hospital Administrative Unit).
Deceleration
Funding
This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.
Conflict of interest
All authors certify that they have no affiliations with or involvement in any organization or entity with any financial interest or non-financial interest in the subject matter or materials discussed in this manuscript.
Disclosures
The study was designed, analyzed, written, and approved by the corresponding author (EDU).
| 1. Reiner A, Dragatsis I, Dietrich P. Genetics and neuropathology of Huntington's disease. Int Rev Neurobiol. 2011;98:325-72. doi: 10.1016/B978-0-12-381328-2.00014-6 https://doi.org/10.1016/B978-0-12-381328-2.00014-6 PMid:21907094 PMCid:PMC4458347 |
||||
| 2. Rüb U, Seidel K, Heinsen H, Vonsattel JP, den Dunnen WF, Korf HW. Huntington's disease (HD): the neuropathology of a multisystem neurodegenerative disorder of the human brain. Brain Pathol. 2016 Nov;26(6):726-740. doi: 10.1111/bpa.12426 https://doi.org/10.1111/bpa.12426 PMid:27529157 PMCid:PMC8029421 |
||||
| 3. Devrim Balaban O, Atbasoglu C. Neuropsychiatric Aspects of Huntington's Disease. Psikiyatride Güncel Yaklaşımlar-Current Approaches in Psychiatry 2022; 14(1):98-112. DOI: 10.18863/pgy.952664 https://doi.org/10.18863/pgy.952664 |
||||
| 4. Hungtington Study Group. Unified Huntington's Disease Rating Scale: reliability and consistency. Mov. Disord. 1996; 11: 136-142. https://doi.org/10.1002/mds.870110204 PMid:8684382 |
||||
| 5. Beglinger LJ, O'Rourke JJ, Wang C, Langbehn DR, Duff K, Paulsen JS; Huntington Study Group Investigators. Earliest functional declines in Huntington disease. Psychiatry Res. 2010 Jul 30;178(2):414-8. doi: 10.1016/j.psychres.2010.04.030 https://doi.org/10.1016/j.psychres.2010.04.030 PMid:20471695 PMCid:PMC3629818 |
||||
| 6. Stroop JR. Studies of interference in serial verbal reactions. Journal of Experimental Psychology. 1935; 18: 643-662. https://doi.org/10.1037/h0054651 |
||||
| 7. Ho AK, Sahakian BJ, Robbins TW, Barker RA, Rosser AE, Hodges JR. Verbal fluency in Huntington's disease: a longitudinal analysis of phonemic and semantic clustering and switching. Neuropsychologia. 2002; 40(8); 1277-1284. doi: 10.1016/s0028-3932(01)00217-2 https://doi.org/10.1016/S0028-3932(01)00217-2 PMid:11931930 |
||||
| 8. Kiely KM, Butterworth P, Watson N, Wooden M. The Symbol Digit Modalities Test: Normative data from a large nationally representative sample of Australians. Arch Clin Neuropsychol. 2014; 29(8): 767-775. doi: 10.1093/arclin/acu055 https://doi.org/10.1093/arclin/acu055 PMid:25352087 |
||||
| 9. Phattanarudee S, Sangthong S, Bhidayasiri R. Association between Sleep Disturbances and Daytime Somnolence in Parkinson's Disease. Eur Neurol. 2018;80(5-6):268-276. doi: 10.1159/000496937 https://doi.org/10.1159/000496937 PMid:30731467 |
||||
| 10. Weintraub D, Mamikonyan E, Papay K, Shea JA, Xie SX, Siderowf A. Questionnaire for Impulsive-Compulsive Disorders in Parkinson's Disease-Rating Scale. Mov Disord. 2012; 27: 242-247. doi: 10.1002/mds.24023 https://doi.org/10.1002/mds.24023 PMid:22134954 PMCid:PMC3537263 |
||||
| 11. Pedersen KF, Alves G, Larsen JP, Tysnes OB, Møller SG, Brønnick K. Psychometric properties of the Starkstein Apathy Scale in patients with early untreated Parkinson's disease. Am J Geriatr Psychiatry. 2012; 20(2): 142-148. doi: 10.1097/JGP.0b013e31823038f2 https://doi.org/10.1097/JGP.0b013e31823038f2 PMid:22064613 |
||||
| 12. Hamilton MA. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960; 23: 56-62. https://doi.org/10.1136/jnnp.23.1.56 PMid:14399272 PMCid:PMC495331 |
||||
| 13. Hamilton M. The assessment of anxiety states by rating. Br J Med Psychol. 1959; 32: 50-55. https://doi.org/10.1111/j.2044-8341.1959.tb00467.x PMid:13638508 |
||||
| 14. Pujol J, Fenoll R, Ribas-Vidal N, Martínez-Vilavella G, Blanco-Hinojo L, et al. A longitudinal study of brain anatomy changes preceding dementia in Down syndrome. Neuroimage Clin. 2018; 18: 160-166. doi: 10.1016/j.nicl.2018.01.024 https://doi.org/10.1016/j.nicl.2018.01.024 PMid:29868444 PMCid:PMC5984600 |
||||
| 15. Veldman MB, Yang XW. Molecular insights into cortico-striatal miscommunications in Huntington's disease. Curr Opin Neurobiol. 2018; 48: 79-89. doi: 10.1016/j.conb.2017.10.019 https://doi.org/10.1016/j.conb.2017.10.019 PMid:29125980 PMCid:PMC5825262 |
||||
| 16. Hedjoudje A, Nicolas G, Goldenberg A, Vanhulle C, Dumant-Forrest C, et al. Morphological features in juvenile Huntington disease associated with cerebellar atrophy - magnetic resonance imaging morphometric analysis. Pediatr Radiol. 2018; 48(10): 1463-1471. doi: 10.1007/s00247-018-4167-z. https://doi.org/10.1007/s00247-018-4167-z PMid:29926145 |
||||
| 17. Youssov K, Dolbeau G, Maison P, Boissé MF, Cleret de Langavant L, et al. Unified Huntington's disease rating scale for advanced patients: validation and follow-up study. Mov Disord. 2013; 28(12): 1717-1723. doi: 10.1002/mds.25654 https://doi.org/10.1002/mds.25654 PMid:24166899 PMCid:PMC5071381 |
||||
| 18. Aylward EH, Schwartz JJ, Machlin S, Pearlson G. Bicaudate ratio as a measure of caudate volume on MR images. AJNR Am J Neuroradiol. 1991; 12(6): 1217-1222 | ||||
| 19. Cheng YF, Liu KC, Yang TM, Xiao Y, Jiang QR, et al. Factors influencing cognitive function in patients with Huntington's disease from China: A cross-sectional clinical study. Brain Behav. 2023 Nov;13(11):e3258. doi: 10.1002/brb3.3258 https://doi.org/10.1002/brb3.3258 PMid:37849450 PMCid:PMC10636378 |
||||
| 20. Batista S, Zivadinov R, Hoogs M, Bergsland N, Heininen-Brown M, et al. Basal ganglia, thalamus and neocortical atrophy predicting slowed cognitive processing in multiple sclerosis. J Neurol. 2012 Jan;259(1):139-46. doi: 10.1007/s00415-011-6147-1 https://doi.org/10.1007/s00415-011-6147-1 PMid:21720932 |
||||
| 21. Cairns NJ, Bigio EH, Mackenzie IR, Neumann M, Lee VM,; Consortium for Frontotemporal Lobar Degeneration. Neuropathologic diagnostic and nosologic criteria for frontotemporal lobar degeneration: consensus of the Consortium for Frontotemporal Lobar Degeneration. Acta Neuropathol. 2007; 114(1): 5-22. doi: 10.1007/s00401-007-0237-2 https://doi.org/10.1007/s00401-007-0237-2 PMid:17579875 PMCid:PMC2827877 |
||||
| 22. Hobbs NZ, Barnes J, Frost C, Henley SM, Wild EJ, Macdonald K, et al. Onset and progression of pathologic atrophy in Huntington disease: a longitudinal MR imaging study. AJNR Am J Neuroradiol. 2010; 31(6): 1036-1041. doi: 10.3174/ajnr.A2018 https://doi.org/10.3174/ajnr.A2018 PMid:20150305 PMCid:PMC7963924 |
||||
| Article View | 394 |
| PDF Download | 231 |